USGovernment-News.Com

USGovernment-News.Com

News on U.S. government agencies, U.S. politics, companies doing business with U.S. federal government. Read U.S. national and local news. This site is not affiliated with United States Government.
Press release distribution service
Home : U.S. Government News Search Engine                          

Home > U.S. Government News > Marketplace :
Home: United State Government News
Home | News | Submit Press Release |

Allergic Conjunctivitis Market is expected to be more than USD 2 Billion market by 2025

(USGovernment-News.Com, September 10, 2019 ) According to Renub Research market research report "Allergic Conjunctivitis Market, Patients, Treated Patients, by Countries (India, China, Japan, US, UK, etc.), Disease Type (SAC, PAC, VKC, AKC, GPC), Drugs Profile (Zerviate, OTX-DP, ADX-102, PRT-2761, etc) Companies, Growth Drivers & Challenges" Allergic Conjunctivitis Market is expected to be more than USD 2 Billion market by 2025.



Conjunctive swelling (tissue covering white portion of the eye) is known as allergic conjunctivitis owing to allergy. Allergic conjunctivitis is caused by allergens in patients such as household dust, mold spores, grass, and trees pollen, chemical fragrances (e.g., perfume or household detergents) and animal dander. Treatment for allergic conjunctivitis involves medication for redness and inflammation due to the conjunctiva. The International Ocular Inflammation Society (IOIS) defines allergic conjunctivitis as a form of eye allergy further categorized into two kinds, seasonal allergic conjunctivitis and perennial allergic conjunctivitis.

Request a free sample copy of the report: https://www.renub.com/request-sample-page.php?gturl=allergic-conjunctivitis-market-p.php


The global market for allergic conjunctivitis will develop as a result of the increasing incidence of multiple allergic conjunctivitis, the expansion of medical infrastructure in developing nations as a result of rapid urbanization and the growth of particulate pollution, increased awareness of allergic conjunctivitis among individuals and the increased aging population are driving the market.



Ophthalmic companies are developing new classes of drugs that target the early and late stages of inflammatory processes or mediators engaged in allergic responses. In animal models, these drugs are tested, which will further assist in defining the next generation of anti-allergic treatment.


Request a free Brochure copy of the report: https://www.renub.com/request-brochure-page.php?gturl=allergic-conjunctivitis-market-p.php


Market Summary:

By Disease Type: Perennial Allergic Conjunctivitis (PAC) and Seasonal Allergic Conjunctivitis (SAC) are having a significant market share in Allergic Conjunctivitis Market. Market and market share of Seasonal Allergic Conjunctivitis (SAC) & Perennial Allergic Conjunctivitis (PAC), Vernal Keratoconjunctivitis (VKC), Atopic Keratoconjunctivitis (AKC) and Giant Papillary Conjunctivitis (GPC) are covered in the report.
By Countries: United States holds the biggest market share and China has the most number of patients population in global allergic conjunctivitis market. Market and market share of India, China, Japan, United States, United Kingdom, France, Germany, Italy and Spain are given in this research report.
By Drugs Profile: The research report covers market of Zerviate, OTX-DP, ADX-102, PRT-2761, CVXL-0074, AK-002, Bertilimumab, Reproxalap, ST-266 and SYL-116011
By Companies: Company Overview, Initiatives and Financial Insight of following companies are given in the research report: Santen Pharmaceutical, Alcon (Novartis), Portola Pharmaceuticals and Ocular Therapeutix.


If the information you seek is not included in the current scope of the study kindly share your specific requirements with our custom research team at info@renub.com


Key Topics Covered :

1. Executive Summary
2. Global Allergic Conjunctivitis Market and Patients Analysis

2.1 Allergic Conjunctivitis Market
2.2 Allergic Conjunctivitis Patient Numbers
2.3 Allergic Conjunctivitis Treated Patient Numbers


3. Share Analysis Global Allergic Conjunctivitis

3.1 Country Market Share
3.2 Patients Population Share
3.3 Treated Patients Population Share
3.4 By Disease Type Share


4. India

4.1 Allergic Conjunctivitis Patient Numbers
4.2 Allergic Conjunctivitis Treated Patient Numbers
4.3 Allergic Conjunctivitis Market


5. China

5.1 Allergic Conjunctivitis Patient Numbers
5.2 Allergic Conjunctivitis Treated Patient Numbers
5.3 Allergic Conjunctivitis Market


6. Japan

6.1 Allergic Conjunctivitis Patient Numbers
6.2 Allergic Conjunctivitis Treated Patient Numbers
6.3 Allergic Conjunctivitis Market


7. United States

7.1 Allergic Conjunctivitis Patient Numbers
7.2 Allergic Conjunctivitis Treated Patient Numbers
7.3 Allergic Conjunctivitis Market


8. United Kingdom

8.1 Allergic Conjunctivitis Patient Numbers
8.2 Allergic Conjunctivitis Treated Patient Numbers
8.3 Allergic Conjunctivitis Market


9. France

9.1 Allergic Conjunctivitis Patient Numbers
9.2 Allergic Conjunctivitis Treated Patient Numbers
9.3 Allergic Conjunctivitis Market


10. Germany

10.1 Allergic Conjunctivitis Patient Numbers
10.2 Allergic Conjunctivitis Treated Patient Numbers
10.3 Allergic Conjunctivitis Market


11. Italy

11.1 Allergic Conjunctivitis Patient Numbers
11.2 Allergic Conjunctivitis Treated Patient Numbers
11.3 Allergic Conjunctivitis Market


12. Spain

12.1 Allergic Conjunctivitis Patient Numbers
12.2 Allergic Conjunctivitis Treated Patient Numbers
12.3 Allergic Conjunctivitis Market


13. Disease Type Global Allergic Conjunctivitis Market

13.1 Seasonal Allergic Conjunctivitis (SAC) & Perennial Allergic Conjunctivitis (PAC)
13.2 Vernal Keratoconjunctivitis (VKC)
13.3 Atopic Keratoconjunctivitis (AKC)
13.4 Giant Papillary Conjunctivitis (GPC)


14. Global Allergic Conjunctivitis Drugs Profile/Pipe Line Drugs

14.1 Zerviate
14.2 OTX-DP (Dexamethasone Insert)
14.3 ADX-102
14.4 PRT2761
14.5 CVXL-0074
14.6 AK-002
14.7 Bertilimumab
14.8 Reproxalap
14.9 ST-266
14.10 SYL-116011


15. Growth Driver

15.1 Rapid Urbanization and Growth of Particulate Pollution
15.2 Increasing Ageing Population & Widespread Use of Medications for Various Eye Diseases


16. Challenges

16.1 Diagnostic Challenges
16.2 Undertreated by Patients


17. Santen Pharmaceutical

17.1 Company Overview
17.2 Initiatives
17.3 Financial Insight


18. Alcon Inc. (Novartis)

18.1 Company Overview
18.2 Initiatives
18.3 Financial Insight


19. Portola Pharmaceuticals Inc.

19.1 Company Overview
19.2 Initiatives
19.3 Financial Insight


20. Ocular Therapeutix Inc.

20.1 Company Overview
20.2 Initiatives
20.3 Financial Insight


About Us

Renub Research is a Market Research and Consulting Company. We have more than 10 years of experience especially in international Business-to-Business Researches, Surveys, and Consulting. We provide a wide range of business research solutions that helps companies in making better business decisions. Our clients rely on our market analysis and data to make informed knowledgeable decisions. Our pertinent analysis helps consultants, bankers and executives to make informed and correct decisions.


Contact Us
Renub Research
Phone: +1-678-302-0700
Email: info@renub.com
Website: www.renub.com
Follow us on LinkedIn: www.linkedin.com/company/renub-research

Renub Research

Rajat Gupta

Market Research, Bus

rajat.gupta@renub.com

Source: EmailWire.Com

Source: EmailWire.com

U.S. Governement News: Politics
  • Presidential Elections
  • Democrates
  • Congress
  • House of Representatives
  • President Obama
  • Republican Party
  • Mitt Romney
  • U.S. Senate
  • U.S. Military
  • U.S. Politics
  • Politics Video Feeds

    U.S. Government Resource Center
    We are pleased to offer you this exciting, new, and entirely free professional resource. Visit our Free Industry resource center today to browse our selection of 600+ complimentary Industry magazines, white papers, webinars, podcasts, and more. Get popular titles including:

    Governing
    Point of Beginning
    Overall Labor Effectiveness (OLE) Achieving a Highly Effective Workforce

    No credit cards, coupons, or promo codes required. Try it today!

    USGovernment-News.Com is a news service of GroupWeb Media LLC